Wire · opportunities
Lupin Receives U.S. FDA Approval For Modafinil Tablets
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 September 2026 · Fusion42 review
Lupin received US FDA approval for Modafinil tablets, a bioequivalent to Provigil, targeting a $70.7 million market in the United States, enhancing its central nervous system portfolio. This approval supports Lupin's strong North American sales growth, with US revenues rising 42.9% YoY in Q1 FY27.
This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 5 Sep 2026 and 7 Sep 2026.
◆ ◆ The Wire takeaway
You can use Lupin's FDA approval as a signal that CNS generics remain a growth path in the US. Launch timing and pricing of their Modafinil will open a window to outpace competitors in this $70 million market.
◆ Coverage
3 sources · first reported 5 Sep 2026 · latest 7 Sep 2026
◆ Related on Wire
◆ Topics